Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study

Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study

BackgroundThe efficacy of neoadjuvant therapy (NAT) comprising dual-target drugs has been confirmed among patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Therefore, we explored the differences in responses to NAT and prognosis between patients with HER2(3+)...

Full description

Saved in:
Bibliographic Details
Main Authors: Sicheng Zhou, Xuhui Qin, Wei Xing, Zhao Xu, Chunlv Wei, Yining Ren, Zixing Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Oncology
Subjects:
breast cancer
human epidermal growth factor receptor 2
targeted therapy
neoadjuvant therapy
pathological complete response
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1530793/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1530793/full

Similar Items